Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

50.80 +0.32 (+0.62%)

Streaming Delayed Price Updated: 3:13 PM EDT, Apr 6, 2026 Add to My Watchlist

Price and Volume

Volume	196,586
Open	50.23
Bid (Size)	50.67 (200)
Ask (Size)	50.85 (100)
Prev. Close	50.48
Today's Range	50.23 - 51.24
52wk Range	29.16 - 59.68
Shares Outstanding	53,145,884
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Supernus Pharma Insider Sells $5.4 Million as Stock Surges 53% in a Year ↗

March 27, 2026

Specializing in CNS therapies, this biopharma firm reported a notable insider sale amid a year of strong stock performance.

Via The Motley Fool

3 Reasons SUPN is Risky and 1 Stock to Buy Instead

March 12, 2026

Supernus Pharmaceuticals has had an impressive run over the past six months as its shares have beaten the S&P 500 by 14.1%. The stock now trades at $53.23, m...

Via StockStory

Performance

YTD	+2.7%	+2.7%
1 Month	-5.7%	-5.7%
3 Month	+2.8%	+2.8%
6 Month	+5.1%	+5.1%
1 Year	+57.4%	+57.4%

More News

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Posts Strong Q4 Beat as CNS Portfolio Accelerates Growth ↗

February 24, 2026

Via Chartmill

Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q4 CY2025: Strong Sales

February 24, 2026

Via StockStory

Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results

February 24, 2026

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

Supernus Pharmaceuticals to Participate in March Investor Conferences

February 23, 2026

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

Supernus Pharmaceuticals (SUPN) To Report Earnings Tomorrow: Here Is What To Expect

February 22, 2026

Via StockStory

Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

February 17, 2026

Via Investor Brand Network

Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

February 17, 2026

From BioMedWire

Via GlobeNewswire

3 Reasons to Avoid SUPN and 1 Stock to Buy Instead

February 16, 2026

Via StockStory

Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026

February 12, 2026

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

1 Cash-Heavy Stock on Our Buy List and 2 We Brush Off

February 08, 2026

Via StockStory

1 Healthcare Stock to Consider Right Now and 2 We Brush Off

January 28, 2026

Via StockStory

2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds

January 25, 2026

Via StockStory

3 Unprofitable Stocks We Steer Clear Of

January 21, 2026

Via StockStory

A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen) ↗

January 15, 2026

Via Chartmill

Regencell Bioscience (RGC) Stumbles into 2026: 8% Year-End Slide Sparks Technical Caution

January 01, 2026

Via MarketMinute

3 Low-Volatility Stocks We’re Skeptical Of

December 31, 2025

Via StockStory

3 of Wall Street’s Favorite Stocks That Concern Us

December 22, 2025

Via StockStory

Optimism Flows From Pot To Psychedelics: Atai Beckley, Supernus Stocks Rise After Analyst Flags Positive Tailwinds From Trump’s Marijuana Order ↗

December 19, 2025

Via Stocktwits

Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back ↗

December 15, 2025

Via The Motley Fool

1 Cash-Heavy Stock for Long-Term Investors and 2 We Turn Down

December 14, 2025

Via StockStory

3 Stocks Under $50 That Concern Us

December 11, 2025

Via StockStory

3 Unprofitable Stocks We Find Risky

December 03, 2025

Via StockStory

Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference

December 03, 2025

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Supernus Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Supernus Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Supernus Pharmaceuticals, Inc. - Common Stock trade on?

Supernus Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Supernus Pharmaceuticals, Inc. - Common Stock is SUPN on the Nasdaq Stock Market

What is the current price of Supernus Pharmaceuticals, Inc. - Common Stock?

The current price of Supernus Pharmaceuticals, Inc. - Common Stock is 50.80

When was Supernus Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Supernus Pharmaceuticals, Inc. - Common Stock was at 04/06/26 03:13 PM ET

What is the market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Supernus Pharmaceuticals, Inc. - Common Stock is 2.70B

How many shares of Supernus Pharmaceuticals, Inc. - Common Stock are outstanding?

Supernus Pharmaceuticals, Inc. - Common Stock has 3B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.